BACKGROUND: The prevalence of metabolic syndrome (obesity, glucose intolerance, low serum high-density lipoprotein cholesterol [HDL-C], high serum triglycerides, hypertension) is high and increasing in parallel with an increasing breast cancer incidence worldwide. HDL-C represents an important aspect of the syndrome, yet its role in breast cancer is still undefined. METHODS: In two population-based screening surveys during 1977-1983 and 1985-1987, serum HDL-C was assayed enzymatically among 38,823 Norwegian women aged 17-54 years at entry. Height, weight, blood pressure, serum lipids, fat and energy intake, physical activity, parity, oral contraceptive use, hormone therapy use, alcohol intake, and tobacco use were also assessed. We used Cox proportional hazards modeling to estimate the relative risk (RR) of breast cancer associated with serum HDL-C levels and to adjust for potential confounding variables. We performed stratified analyses to evaluate effect modification by body mass index (BMI) and menopausal status. All statistical tests were two-sided. RESULTS: During a median follow-up of 17.2 years, we identified 708 cases of invasive breast cancer. In multivariable analysis, the risk of postmenopausal breast cancer was inversely related to quartile of HDL-C (P(trend) =.02). Among women with HDL-C above 1.64 mmol/L (highest quartile) versus below 1.20 mmol/L (lowest quartile), the relative risk was 0.75 (95% confidence interval [CI] = 0.58 to 0.97). The HDL-C association was confined to women in the heavier subgroup (BMI > or =25 kg/m2), for whom the relative risk of postmenopausal breast cancer in those with HDL-C above 1.64 mmol/L versus below 1.20 mmol/L was 0.43 (95% CI = 0.28 to 0.67; P(trend)<.001; P(interaction) =.001). CONCLUSION: Low HDL-C, as part of the metabolic syndrome, is associated with increased postmenopausal breast cancer risk.
BACKGROUND: The prevalence of metabolic syndrome (obesity, glucose intolerance, low serum high-density lipoprotein cholesterol [HDL-C], high serum triglycerides, hypertension) is high and increasing in parallel with an increasing breast cancer incidence worldwide. HDL-C represents an important aspect of the syndrome, yet its role in breast cancer is still undefined. METHODS: In two population-based screening surveys during 1977-1983 and 1985-1987, serum HDL-C was assayed enzymatically among 38,823 Norwegian women aged 17-54 years at entry. Height, weight, blood pressure, serum lipids, fat and energy intake, physical activity, parity, oral contraceptive use, hormone therapy use, alcohol intake, and tobacco use were also assessed. We used Cox proportional hazards modeling to estimate the relative risk (RR) of breast cancer associated with serum HDL-C levels and to adjust for potential confounding variables. We performed stratified analyses to evaluate effect modification by body mass index (BMI) and menopausal status. All statistical tests were two-sided. RESULTS: During a median follow-up of 17.2 years, we identified 708 cases of invasive breast cancer. In multivariable analysis, the risk of postmenopausal breast cancer was inversely related to quartile of HDL-C (P(trend) =.02). Among women with HDL-C above 1.64 mmol/L (highest quartile) versus below 1.20 mmol/L (lowest quartile), the relative risk was 0.75 (95% confidence interval [CI] = 0.58 to 0.97). The HDL-C association was confined to women in the heavier subgroup (BMI > or =25 kg/m2), for whom the relative risk of postmenopausal breast cancer in those with HDL-C above 1.64 mmol/L versus below 1.20 mmol/L was 0.43 (95% CI = 0.28 to 0.67; P(trend)<.001; P(interaction) =.001). CONCLUSION: Low HDL-C, as part of the metabolic syndrome, is associated with increased postmenopausal breast cancer risk.
Authors: Anna M Kucharska-Newton; Wayne D Rosamond; Jane C Schroeder; Ann Marie McNeill; Josef Coresh; Aaron R Folsom Journal: Lung Cancer Date: 2008-03-14 Impact factor: 5.705
Authors: Geoffrey C Kabat; Mimi Kim; Rowan T Chlebowski; Janu Khandekar; Marcia G Ko; Anne McTiernan; Marian L Neuhouser; Donna R Parker; James M Shikany; Marcia L Stefanick; Cynthia A Thomson; Thomas E Rohan Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-06-30 Impact factor: 4.254
Authors: Qian Wu; Tomonori Ishikawa; Rosa Sirianni; Hao Tang; Jeffrey G McDonald; Ivan S Yuhanna; Bonne Thompson; Luc Girard; Chieko Mineo; Rolf A Brekken; Michihisa Umetani; David M Euhus; Yang Xie; Philip W Shaul Journal: Cell Rep Date: 2013-11-07 Impact factor: 9.423
Authors: Lea M Beaulieu; Brandi R Whitley; Theodore F Wiesner; Sophie M Rehault; Diane Palmieri; Abdel G Elkahloun; Frank C Church Journal: Bioessays Date: 2007-10 Impact factor: 4.345
Authors: Yukiko Morimoto; Shannon M Conroy; Nicholas J Ollberding; Susanne M Henning; Adrian A Franke; Lynne R Wilkens; Marc T Goodman; Brenda Y Hernandez; Loïc Le Marchand; Brian E Henderson; Laurence N Kolonel; Gertraud Maskarinec Journal: Cancer Causes Control Date: 2012-08-21 Impact factor: 2.506